A growing number of cancers are treated with FDA-approved anti-PD-1 or anti-PD-L1 antibodies blocking PD-1 or PD-L1 with response rates for PD-1/PD-L1 blockade in approved indications ranging from 13 to 69% depending on tumor type11,17. This evidence concerns the gene PDCD1 and neoplasm.